Table 1.

CMV reactivation time point and antiviral treatment

Animal ID	Immunosuppressive Therapy	TBI (cGy)	Day of Reactivation	Day of CMV >1,000 copies/mL	Day of CMV >10,000 copies/mL	Day of Initiation of Antiviral Treatment	Antiviral Treatment	Cause of Euthanasia
90-39	CyA	300	0	0	12	17	GCV, VGC	CMV viremia
90-15	CyA	300	19	19	23	23	GCV, VGC, Foscarnet	Scientific Endpoint
6C64	CyA	300	5	5	19	2	Foscarnet, GCV, VGC	Scientific Endpoint
6C1	CyA	300	7	12	NA	7	GCV	Scientific Endpoint
90-47	CyA	300	NA	NA	NA	NA	NA	CMV viremia
90-7	CyA	300	1	1	19	10	GCV, VGC	Scientific Endpoint
90-1	CyA	300	NA	NA	NA	NA	NA	Scientific Endpoint
SA196A	Rapamycin	300	8	8	29	30	GCV	Scientific Endpoint
AM538C	Rapamycin	250	26	26	34	34	GCV	Scientific Endpoint
AK746F	Rapamycin	250	26	26	28	29	GCV	Scientific Endpoint
BF418F	Rapamycin	250	6	NA	NA	13	GCV, Foscarnet, Cidofovir	Scientific Endpoint
AG531J	Rapamycin	250	16	20	NA	20	GCV	Scientific Endpoint
BM12B	Rapamycin	250	29	NA	NA	NA	NA	Scientific Endpoint
AF201G	Rapamycin	250	8	26	NA	19	GCV	GVHD
V59M	Rapamycin	250	10	NA	NA	25	GCV	GVHD
AJ606D	Rapamycin	250	29	33	NA	36	GCV	Scientific Endpoint
AH260F	Rapamycin	250	9	9	32	32	GCV	Scientific Endpoint
AT468G	Rapamycin	250	11	NA	NA	17	GCV, Foscarnet	Renal failure/Infection
BY648F	Rapamycin	250	10	NA	NA	16	GCV	Scientific Endpoint
AP532B	Rapamycin	250	30	49	NA	43	GCV	GVHD
F813M	Rapamycin	250	4	28	36	27	GCV	GVHD

“Day” represents the number of days after conditioning was completed at which the first CMV positive sample was detected (Day of Reactivation), CMV copies/mL threshold was reached (Day of CMV >1,000 copies/mL or Day of CMV >10,000 copies/mL), or the time point when the antiviral treatment was started (Day of initiation of antiviral treatment). 90-1 (CMV seronegative), 90-47 and BM12B did not receive antiviral treatment. NA, not applicable; CMV, cytomegalovirus; CyA, cyclosporine A; TBI, total body irradiation; GCV, ganciclovir; VGC, valganciclovir.